BIORCHESTRA Co., Ltd.
We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift for neurodegenerative disease.
We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift for neurodegenerative disease.
BIORCHESTRA Co., Ltd. is a biotech company founded in 2016 and headquartered in the United States. The company specializes in the development of RNA-based therapeutics with the goal of fundamentally changing the approach to treating neurodegenerative diseases. With the slogan "We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift for neurodegenerative disease," BIORCHESTRA aims to shift the therapeutic paradigm from treating symptoms to providing a cure.
The company recently secured a KRW54.50B Series C investment on 22 February 2022. The investment was made by a group of prominent investors including Smilegate Investment, DAYLI Partners, IMM Investment, LSK Investment, Widwin Investment, Quantum Ventures Korea, SBI Investment Korea, Chong Kun Dang, GS Holdings, and E&Venture Partners.
BIORCHESTRA focuses on the Biopharma, Biotechnology, Health Care, and Health and Wellness industries and is currently making substantial progress in clinical development. The company is actively seeking global partners for collaboration in research and development as well as commercialization efforts.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | KRW54.50B | 10 |
|
22 Feb 2022 |
| Series B | KRW12.00B | - | 16 Dec 2020 | |
| Venture Round | KRW5.00B | - | 21 Aug 2019 | |
| Non Equity Assistance | Unknown | - | 01 Mar 2017 |
No recent news or press coverage available for BIORCHESTRA Co., Ltd..
We care about your data, and we'd love to use cookies make your experience better.
